United Cancer Centers

Addressing Accessibility and Affordability for the Sickest Cancer Patients by Building Integrated Right To Try Outpatient Clinics.

About United Cancer Centers

United Cancer Centers, Inc. (“UCC”), comprises a collection of US-based outpatient clinics that seek to redefine the concept of informed decision making for cancer patients by providing access to a wider array of both FDA-approved and investigational treatment options.

The goal of United Cancer Centers is to provide comprehensive cancer treatment that addresses the glaring issues that cancer patients face, such as the need for rapid access to information regarding treatment options, access to investigational therapies once all standard of care options are exhausted, and the affordability of care.

Translational Medicine

Right To Try Outpatient Clinics

Options For Cancer Patients

Collectively, the goal of United Cancer Centers is to take a process that typically takes 10 to 15 years with the U.S. FDA and to time collapse this into as little as 18 months.

By shortening the gap between scientific discovery and implementation, we can ensure that patients have a feasible and understandable pathway to access the most cutting edge therapeutic interventions. Our hope is that this process can better facilitate the pathway to a cure for cancer through translational medicine.

Introducing the UCC Integrated Right-To-Try Outpatient Clinic Model


Our Long Term Vision at United Cancer Centers is to provide a comprehensive array of treatments that help patients with true informed decision making. We help patients navigate all the possible therapeutic drugs to treat their condition including standard of care treatments (radiation, chemotherapy, surgery and immunotherapy), clinical trials, and other pathways for obtaining allowable cancer treatments such as through the Right-to-Try legislation.

Immune System & Microbiome
Profiling Of The Patient

Molecular & Genetic Analysis
 Of The Cancer

Diagnosis &
 Treatment Plan

1

Standard Of Care
Cancer Therapies

  • Chemotherapy
  • Targeted Therapies (Small Molecules, Antibodies)
  • Surgical Resection
  • Cryoablation
  • Intratumoral Embolization
  • Radiotherapy

2

Immunotherapy

  • Access to Checkpoint Inhibitors through compassionate use, Right-to-Try, or off-label prescription
  • Adjuvants to boost immunity: Cytokines, toll-like receptor agonist drugs

3

Compassionate Use and
Right-to-Try Cancer Therapies

  • FDA Approved Therapies
  • Expanded Access (Compassionate Use)
  • Right-to-Try Access (Phase 1 Complete)

4

Integrative Cancer Treatments

  • Cancer Management Diets; personalized diets
  • Customized probiotics & detoxification for gut health
  • Immune System Support

Mission Statement & Goals of United Cancer Centers

  • To develop treatmen​​​​​t options and inform cancer patients in an individualized manner
  • To leverage the Right-to-Try law and other pathways to facilitate access of patients to validated immunotherapy by navigating drug development and regulatory considerations on behalf of the patient
  • To utilize the Right-to-Try law as a pathway for maximizing the affordability of drug therapies for cancer patients
  • To advance our specific research and development efforts towards bringing novel FDA-investigated immunotherapy treatment options to patients

Understanding the Potential Value of the Right-to-Try Law for the Patient

Cost Reduction For Patient

  • Addressing the affordability issue with standard of care therapies
  • Access to bio-similar drugs approved ex-US to eliminate international price discrepancies
  • Access to investigational checkpoint inhibitor immunotherapies targeting validated pathways "at cost"

Providing Patients Hope

  • Access to investigational drugs should all conventional approaches fail
  • Genomics counselor an central UCC consultancy will guide patients in the evaluation of drugs in clinical development that may have a superior signal of efficacy compared to the standard of care


At United Cancer Centers, our goal is to provide patients with the best-suited immunotherapy treatments for their individual cancer.

Cost Containment Strategies & Comparison


Given the terrible burden of cancer, coupled with all of these obstacles to cancer treatment, there is a dire need for patient-centered cancer care facilities that can centralize the processes of treatment decision-making and delivery of comprehensive cancer care.


At the same time, there is an urgent need to address the gaps that exist in access, affordability, and transparency of the process of procuring and paying for therapeutics such that the benefits and risks can be considered by patients and their families.


Limitations in Patient Access
to Investigational Drugs

One potential use of the Right to Try law is to expand access to approved drugs with the goal of removing price discrepancies


It is our goal to leverage the Right-to-Try law as well as conventional FDA pathways to facilitate patient access to validated immunotherapy by navigating the pharmaceutical landscape and the regulatory considerations on behalf of patients. In addition, we strive to utilize the Right-to-Try law as a pathway for maximizing the affordability of drug therapies for cancer patients.

Currently, Compassionate Use has limited widespread utility due to high barriers to entry

United Cancer Center's Management Team

 Kenneth Webster, Esq. 

Chief Executive Officer and General Counsel,
UCC Board of Directors

For nearly 20 years, Ken provided legal representation to several of the largest providers of institutional healthcare in the United States. In that capacity, Ken’s primary focus was as trial counsel in medical malpractice cases defending all manner of care providers in Federal and State courts as well as before various licensing and review boards on behalf of individual practitioners.

In addition, he routinely consulted on policy and procedure formation, regulatory compliance, by law development, staff in-servicing and risk reduction strategies. Ken has lectured frequently at the national gatherings of institutional healthcare providers. Ken honed his counseling, litigation and management skills as a partner and shareholder in a national law firm where he opened and managed multiple offices as part of the firm’s regional operations in California and Nevada.

 Ken is excited to bring nearly two-decades of experience at the intersection of law and healthcare to benefit patients and support the advancement of investigational medicine.

 Francesco Marincola, M.D.

Chief Medical Officer

As past president of the Society for the Immunotherapy of Cancer and Editor-in-Chief of the Journal of Translational Medicine and with over 600 peer-reviewed scientific papers, Dr. Marincola is considered one of the world’s leading experts in cancer immunotherapy.

 Dr. Marincola was Distinguished Research Fellow at AbbVie, Inc. He also was Chief Research Officer of Sidra Medical and Research Center in Doha, Qatar. Prior to that, Dr. Marincola was Chief Infectious Disease and Immunogenetics Branch at the U.S. National Institutes of Health. Dr. Marincola earned his M.D. from the University of Milan and completed his clinical training in Surgery and scientific training at Stanford University from 1980 – 1990.

Michael N. Liebman, Ph.D.

Chief Scientific Officer

Michael N. Liebman, Ph.D. is the Managing Director of IPQ Analytics, LLC and of Strategic Medicine, Inc, and Strategic Medicine, BV (the Hague, NL) after serving as the Executive Director of the Windber Research Institute from 2003-2007.  He is also an Adjunct Professor of Pharmacology and Physiology at Drexel College of Medicine and Adjunct Professor of Drug Discovery, First Hospital of Wenzhou Medical University.  Previously, he was Director, Computational Biology and Biomedical Informatics at the University of Pennsylvania Cancer Center 2000-2003.  He served as Global Head of Computational Genomics at Roche Pharmaceuticals and Director, Bioinformatics and Pharmacogenomics at Wyeth Pharmaceuticals, Director of Genomics for Vysis, Inc.  He is a co-founder of Prosanos, Inc (now United BioSource) (2000). He was on the faculty of Mount Sinai School of Medicine in Pharmacology and Physiology/Biophysics.   He serves on 14 scientific advisory boards and is on the Board of Directors and chairs the Science Committee of the Nathaniel Adamczyk Foundation for Pediatric ARDS and is an Advisor to the American Heart Association Science and Technology Accelerator.  

Michael is Chair of the Informatics Program of the PhRMA Foundation and also Chair of its new program in Translational Medicine and Therapeutics and is a member of the PhRMA Scientific Advisory Board.  He is on the Advisory Board of the International Society for Translational Medicine and on the Editorial Board for the Journal of Translational Medicine, for Clinical and Translational Medicine and for Molecular Medicine and Therapeutics and the International Park for Translational Biomedicine (Shanghai).  He is an Invited Professor at the Shanghai Center for Bioinformatics Technology.  His research focuses on computational models of disease progression stressing risk detection, disease process and pathway modeling and analysis of lifestyle interactions and causal biomarker discovery and focuses on moving bedside problems into the research laboratory to improve patient care and quality of life.  Recent activities also include computational approaches to disease modeling, patient and disease stratification, drug safety, reduction of animal testing, the use of genomic data in healthcare, and both qualitative and quantitative risk assessment in health care and the life sciences.

 Vijay Mahant  MS. Ph.D


Vice President of Precision Oncology

Vijay Mahant received his MS., Ph.D., and first post-doctorate from LUT (UK), He received his second post-doctorate from the UT Health Science Center at Houston/MD Anderson, TX, USA).  Dr. Mahant is a scientist and an entrepreneur with more than 35 years of experience in immuno-and precision medicine (oncology, cardiology, pain management and psychiatric, etc).  He has held executive positions and he is a founder/co-founder of diagnostic companies, He is currently the CEO of MediLite Diagnostika Inc.


  Dr. Mahant has been involved in fund raisings, Initial Public Offerings (IPOs) and he has 30 issued patents and 10 patents pending; he has authored and/or co-authored publications in journals and science books; he is an associate editor of Journal of Translation Medicine. Dr. Mahant has managed intellectual property, including in-and out -licensing. He developed several FDA cleared products with multimillion dollars in revenues. 


Dr. Mahant is on the SAB/MAB of Batu Biologics (an oncology company), CHIPSA Hospital (an oncology hospital) , Trutino Biosciences (an oncology company and developing an IL2-peptide based drug),  TulyNode (an autologous immune therapy company). SNET (an oncology company focused on  autologous immuno-therapy and “targeted” drug delivery), Immunicom (immunophoreis device for treating cancer) and APT (focused on preeclampsia).
Ed Clay

Ed Clay

President and UCC Board Member

Ed Clay is a former professional Mixed Martial Arts fighter, at one point, ranked as high as number 9 in the world. He ran one of the largest Mixed Martial Arts schools in the United States with multiple students fighting in events such as the Ultimate Fighting Championships.

His clothing brand, Gameness, which was acquired in 2011, was the largest supplier of Brazilian Jiu-Jitsu Martial Arts uniforms in the world. He was a MMA co-host of a highly rated FM sports radio show for 8 years. He is the former owner and Editor in Chief of Submission Fighter magazine.

 In 2015, along with his 2 partners Scott Nelson and Deddrick Perry, Clay acquired the CHIPSA hospital in Tijuana, Mexico. Ed is interested in developing solutions to address some of the glaring issues with cancer management in the United States and is a strong supporter of integrative immunotherapy: the concept of bringing together the conventional and alternative sides of medicine to improves patient outcomes.

Ed is considered a pioneer in the direct response internet marketing space. His vast experience with messaging and online media along with 18 years experience as an entrepreneur gives him a unique skill set as President of United Cancer Centers.

Scott Nelson

Scott Nelson

Chief Marketing Officer and UCC Board Member

Scott Nelson has a long history dating back to 1984 with programing and technology platforms. Over the years Scott saw that every business needs good marketing to drive sales.

Marketing automation and e-commerce became his passion before his shift in to health care. In 1996 long before it became popular Scott co-founded one of the first online lifestyle magazines. He was travel blogging before blogs became popular. He created a life style brand On The Mat (OTM) by competing himself in martial arts around the world. The site’s popularity allowed him branched out in to 3 successful lifestyle apparel clothing brands.  

Building on the success of his brands he went on to open 13 brick and mortar retail locations. The brand's popularity quickly grew and manufacturing outside of the USA became a necessity. Scott then successfully navigated overseas manufacturing of garments and hard goods in China, Taiwan, Pakistan, and Brazil.

Scott leveraged his vast experience in manufacturing and marketing to begin consulting for specializing in sourcing niche markets and selling them online. In 2008 he authored a book on launching online brands from development & manufacturing to full online product launch. Scott has honed his digital marketing over the last 23 years, staying ahead of the curve becoming an electronic automation ninja using platforms such as his favorite InfusionSoft. 

He specializes in online sales funnel optimization and lead generation. Currently Scott owns and manages multiple online business but his primary passion is fighting cancer and working with UCC.

Scott Nelson is a co-founder and owner of the CHIPSA Hospital where he implemented CHIPSA's entire patient experience platform from lead, to in hospital and, automated after care follow up. Scott also oversaw the CHIPSA's ERP system implementation in full compliance with the COFEPRIS (Mexico's FDA) regulations.  

Deddrick Perry Headshot

Deddrick Perry

SVP Clinical Operations and UCC Board Member

Deddrick Perry is an investor and entrepreneur with over 9 years experience as a principal and treasury manager. Deddrick specializes in strategic structuring of assets and managing liquidity across multinational companies and currencies.

Mr. Perry has served on several boards and is a 2015 NLC Fellow and has extensive experience developing political operatives. Prior to 2010, Mr. Perry was a sales coach and consultant in the Chicago advertising industry.

Deddrick is the Co-Founder and Chief Operating Officer of CHIPSA Hospital and The North Beach Clinic; and principal Co-Founder of FirstMedic Sa.Cv Hospital Corp and Servicios Medicos Clinical Corp in Mexico.

J. Christopher Mizer

Chief Business Officer

J. Christopher Mizer founded Vivaris in June of 1998. Vivaris (formerly Lake Erie Capital) invests in and acquires middle-market businesses in a broad range of industries that are leaders in their market niches. Mr. Mizer serves as the chairman of each of the portfolio companies and guides key strategic decisions and their execution.

He also serves as the operating president on an interim basis when companies are going through periods of ownership succession and new management team members are being assembled. Mr. Mizer is a former Vice President and Officer of the investment banking division of Key Capital Markets, where he focused on merger, acquisition, and financing projects for Fortune 500 clients, private companies, and successful entrepreneurs.

Prior to joining Key Corp., he was Consultant in the Capital Markets practice with Ernst & Young. He began his career as a Research Assistant with The Center for Economic Issues, a think-tank focused on economic development.

 He earned the B.S. (biology, applied math), B.A. (economics), M.S. degrees (biology - neurogenetics), and MBA (finance, accounting) degrees from Case Western Reserve University.

In The News

United Cancer Centers was recently featured in a Forbes Magazine article that discussed Security Token Offerings, which is UCC's primary investment strategy, and how it could be the future of raising capital investments. In the article, United Cancer Center's CEO, Ken Webster Asq., discusses why we are pursing an Security Token Offering.

"We have interest in the concept of fractionating distribution based investment contracts. This allows for multiple investors to participate in a revenue share model, and the recent establishment of STO exchanges provide a platform to potentially liquidate these smart contracts in the near future."

To read the full article,
click here.

Click the link Below For more information on
the United Cancer Center’s Mission

Copyright 2019 United Cancer Centers